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http://dx.doi.org/10.1016/j.jmii.2012Background: Imipenem-resistant Acinetobacter baumannii (IRAB) poses a great threat to
healthcare systems. Production of carbapenem-hydrolyzing class D b-lactamases (CHDLs) is
the major mechanism for imipenem resistance. In this study, we found a high prevalence of
IRAB carrying a gene encoding CHDL, blaOxA-23, in central Taiwan and elucidated the molecular
characteristics and possible mechanisms of the spread of these isolates.
Methods: During 2007, we collected 291 nonrepetitive A baumannii isolates from 10 teaching
hospitals in Taiwan. The antimicrobial susceptibility of the isolates was determined by agar
dilution or Etest. The genes encoding carbapenemase and related structure were detected
by polymerase chain reaction mapping and sequencing, and the clonal relationship of the
isolates was analyzed by pulsed-field gel electrophoresis. Plasmid localization of blaOxA-23
was determined by extraction of plasmid with commercial kit and Southern blot analysis.
Results: Among 142 IRAB isolates, 30 harbored the blaOxA-23. The prevalence of IRAB with
blaOxA-23 was highest in central Taiwan compared to other areas [24.8% (27/109) vs. 1.6%
(3/182); p < 0.001]. These IRAB with blaOxA-23 were also resistant to other antimicrobialInfectious Diseases, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112,
il.com (S.-C. Kuo).
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420 M.-H. Lee et al.agents, except colistin. The PCR methods showed the presence of blaOxA-51 in all isolates. We
could exclude clonal spreading due to the diversity of the pulsotype. The blaOxA-23 gene was
detected in the plasmids of 6 isolates. Tn2006 was present in 22 (73.3%) isolates, and
Tn2008, in 6 other isolates (26.7%). Two strains had blaoxa-23eDATPase but lacked upstream
ISAba1.
Conclusion: The high prevalence of blaOxA-23-harboring IRAB in central Taiwan might be
attributed to the transposition event of Tn2006.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Figure 1. Prevalence of Acinetobacter baumannii carrying
blaOxA-23 from 10 teaching hospitals in Taiwan. Percentage was
presented as the number of A baumannii carrying blaOxA-23
divided by the number of all A baumannii isolates in different
hospitals.Introduction
Acinetobacter baumannii has emerged as a major pathogen
causing a multitude of infections, especially in critically ill,
immunosuppressed patients and those treated with broad-
spectrum antibiotics.1,2 Owing to the ability of bacteria to
develop different mechanisms of resistance and the
increasing number of vulnerable hosts, the prevalence of
multidrug resistant A baumannii (MDRAB) rose in the past
few decades. Unfortunately, the treatments of choice are
limited.3 The resistance to carbapenem, which was one of
the few therapeutic options available, is now a worldwide
problem.4e6 In Taiwan, in 2000, the imipenem-resistant
rate in the intensive care units of 5 major hospitals was
22%,3 whereas in 2010, it was 66.8%.7 Although resistance to
carbapenem has been associated with the loss of outer-
membrane porins or overexpression of efflux pumps,
production of Ambler class B metallo-b-lactamases and
carbapenemase-hydrolyzing class D b-lactamases (CHDLs)
are the most common mechanisms.8 Three (blaIMP-like,
blaVIM-like, and blaSIM-1) of the 6 known metallo-b-lacta-
mases have been identified in IRAB, but these are less
prevalent than CHDLs, which include blaOxA-23-like, blaOxA-24-
like, blaOxA-51-like, and blaOxA-58-like.
9,10 blaOxA-51-like is
intrinsic to A baumannii, while other CHDLs genes were
acquired. The distribution of A baumannii carrying these
different acquired CHDLs genes varies among different
regions and even different hospitals.11,12 The most common
acquired CHDL gene of imipenem-resistant A baumannii
(IRAB) in many Asia-Pacific countries is blaOxA-23,
13e16 and
a high prevalence of bacterial strains carrying blaOxA-23 has
been reported in hospitals in central Taiwan.17,18 The
blaOxA-23 gene can be carried by transposons such as
Tn2006, Tn2007, and Tn2008.19 In this study, we aimed to
investigate the distribution and characteristics of A bau-
mannii carrying blaOxA-23 in Taiwan. We also propose
possible ways of spreading of blaOxA-23-carrying stains.
Materials and methods
Bacterial isolates and identification
We collected 367 nonrepetitive isolates of Acinetobacter
species from 10 teaching hospitals located in different
areas in Taiwan from June 2007 to September 2007 (Fig. 1).
Four hospitals are located in northern (N) Taiwan, 3 in
central (C) Taiwan, and 3 in southern (S) Taiwan. The
isolates were initially stored at 70 C in trypticase soy
broth (Difco Laboratories, Detroit, MI, USA) supplementedwith 15% glycerol. The A baumannii species was identified
at the Taipei Veterans Hospital, using a multiplex poly-
merase chain reaction (PCR) method for detection of
specific 16S23S rRNA intergenic spacer present in A bau-
mannii as described previously.20,21 Those confirmed as A
baumannii were selected for further studies.
Antimicrobial susceptibility testing
The minimal inhibitory concentration (MIC) of isolates was
determined by the agar dilution method according to the
guidelines provided by the Clinical and Laboratory Stan-
dards Institute (CLSI)22 or Etest (bioMe´rieux, Marcy-
L’Etoile, France). Susceptibility was interpreted based on
CLSI breakpoints or manufacturer’s instructions. Antimi-
crobials including meropenem, imipenem, colistin, tigecy-
cline, sulbactam, amikacin, ticarcillin, piperacillin,
ceftazidime, cefepime, and ciprofloxacin, were tested.
Pulsed-field gel electrophoresis
The clonality of isolates carrying blaOxA-23 was determined
with pulsed-field gel electrophoresis (PFGE) as described
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fragments were subjected to PFGE in 1% SeaKem Gold
agarose gels (Cambrex Bio Science, Rockland, ME, USA) in
0.5 TBE buffer (45 mM Tris, 45 mM boric acid, 1.0 mM
EDTA, pH 8.0). The stained gel was photographed and
analyzed by BioNumerics software (Applied Maths, Sint-
Martens-Latem, Belgium) to generate a dendrogram of
relatedness among these isolates. Isolates with >85%
similarity were grouped as the same clone.23
Identification of CHDLs
PCR with primers targeting blaOxA-23-like, blaOxA-24-like,
blaOxA-58-like, and blaOxA51-like
24 were used to detect genes
encoding common CHDLs. Primers for ISAba1F and OXA-
likeR were used to detect the presence of ISAba1
upstream of different carbapenemases genes.25,26
Determinationof theplasmid localizationofblaOxA-23
The plasmid was extracted with plasmid DNA Miniprep Kit
(Bioman, Taipei, Taiwan) or a plasmid Maxi Kit (Qiagen,
Valencia, CA, USA). The localization of blaOxA-23 was
detected by Southern blot.27 After hybridization with
a PCR-generated probe derived from primers targeting
blaOxA-23 (5
0-TTTACTTGCTATGTGGTTG-30 and 50-CATTTCT-
GACCGCATTTC-30), the band was visualized by digoxigenin
(DIG) DNA labeling and detection kit (Roche Diagnostics,
Basel, Switzerland) according to the manufacturer’s
instructions.
Identification of Tn2006, Tn2007, and Tn2008
PCR mapping was used to detect Tn2006, Tn2007, and
Tn2008. Primer locations are shown in Fig. 2. The common
region of Tn2006 and Tn2008 (923 bp, from blaOxA-23 to
DATPase) was amplified using primers P3 (Tn2006OXA23; 5’-
GTCTATCAGGAACTTGCGCG-3’) and P5 (TN2008ATPase; 5’-
GGCTCATTACAGTCAGGTACAAGT-3’). PCR for Tn2006 was
performed with primers P3 and P4 (Tn2006ISAba1; 5’-
GCAAGGCTTTAGATGCAGAAGA-3’) to amplify the region
(2237 bp) between blaOxA-23 and ISAba1 in Tn2006. PCR
targeting ISAba4 (Tn2007) was performed as previously
described.28 Amplified DNA products were resolved by
electrophoresis in agarose gels (2% w/v), stained withFigure 2. Location of primers used for the detection of
Tn2006 and Tn2008 in this study.ethidium bromide, purified according to the manufacturer’s
instruction, (Geneaid Biotech Ltd, Taipei, Taiwan), and
processed for DNA sequencing by a commercial company
(Mission Biotech, Taipei, Taiwan).
Consumption of imipenem and meropenem per 100
person-days in different areas
The National Health Insurance program covers 99% of the
population in Taiwan. Computerized claims data are
collected and stored in the National Health Insurance
Research Database by the National Health Research Insti-
tute. We retrospectively retrieved inpatients’ claim data
from 2007. We calculated for each patient the dose of
imipenem and meropenem and the total person-day to
obtain the defined daily dose per 100 person-day in
northern, central, and southern areas, which were defined
according to the location of the hospitals. The northern
area included Taipei and New Taipei City; the central area
included Taichung City and its county and Changhua; and
the southern area included Tainan City and its county and
Kaohsiung City and its county.
Results
Of 291 isolates confirmed to be A baumannii, 142 (48.8%)
were resistant to imipenem. The imipenem-resistance rate
in northern, central, and southern Taiwan was 39.3% (42/
107), 56.9% (62/109), and 50.7% (38/75), respectively. The
defined daily doses of carbapenem per 100 person-days in
northern, central, and southern areas were 1.43, 1.33, and
1.50, respectively. Among IRAB isolates, 30 (21.1%)
harbored blaOxA-23. The prevalence of IRAB with blaOxA-23
was highest in central Taiwan (Fig. 1), accounting for 24.8%
(27/109) of all isolates, compared to that in the northern
(2.8%, 3/107) and southern areas (0%, 0/75; both
p < 0.001).
Antimicrobial susceptibility testing
The antimicrobial susceptibility tests (Supplementary Table
1) revealed that strains carrying blaOxA-23 were also resis-
tant to many other commonly used antimicrobial agents.
The resistance rates to ticarcillin, sulbactam, amikacin,
ceftazidime, cefepime, piperacillin, imipenem, mer-
openem, and ciprofloxacin were all higher than 90%.
Colistin-resistant isolates were not found. However, the
MICs of tigecycline among 9 isolates (30%) were more than
2 mg/L by using Etest.
Detection of other carbapenemase genes and
surrounding genetic structure of blaOxA-23
Most of the isolates carrying blaOxA-23 (28, 93.3%) had
ISAba1 upstream the blaoxa-23 gene. All isolates contained
blaOxA-51 but only 3, which did not belong to the same clone
but were present in the same hospital, had ISAba1
upstream of blaOxA-51 (Fig. 3). A strain, which did not have
ISAba1 preceding the blaOxA23 or blaOxA51, expressed
blaOxA58, and the MICs of imipenem and meropenem were
Figure 3. Molecular characteristics of Acinetobacter baumannii carrying blaOxA-23 in Taiwan. The results of pulsed-field elec-
trophoresis are shown, followed by the plasmid patterns, localization of blaOxA-23, transposon types, and presence of ISAba1
upstream of blaOxA-51 from the third to the sixth columns. ND Z not detected.
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Methods, we found that the common region of Tn2006 and
Tn2008 was detected in all strains, and the region specific
for Tn2006 was positive in 22 (73.3%) isolates (Fig. 3).
Tn2008 was present in 6 other isolates (26.7%), whereas
blaOxA23eDATPase but not upstream ISAba1 was present in
2 isolates. No ISAba4 was found, indicating there was no
Tn2007 in any of these strains.
Clonal relationship and plasmid study of the
isolates
The PFGE analysis showed no major clustering among the
isolates (Fig. 3). Five of the 6 isolates with Tn2008 were
collected from the same hospital, and 4 of them belonged
to the same clone. Twenty-four isolates were positive for
the plasmid, as determined using standard extraction
methods. Electrophoresis showed 11 different plasmid
patterns (Fig. 3). Isolates with the same plasmid pattern
(e.g., Groups 1, 3, and 4) did not necessarily belong to the
same pulsotype, but isolates with the same plasmid pattern
were present in the same hospital. Using of the methods
described above, the blaOxA-23 gene was detected in plas-
mids of Group 1, 11, and 6 (data not shown).
Discussion
Our study revealed that blaOxA-23 was mostly found in IRAB
isolates collected in central Taiwan, whereas the preva-
lence of isolates with blaOxA-23 was low in other areas. The
presence of Tn2006 and Tn2008 in these isolates together
with the diversity of the pulsotypes indicated that thepreferred mechanism of spread of blaOxA-23 was via trans-
posons. Clonal spread played a minor role, especially in
isolates harboring Tn2008 in Hospital C3. The spread of
blaOxA-23 via plasmid dissemination cannot be excluded with
the use of current method.
As observed in other Asian countries,29 our study
revealed that the prevalence of IRAB in Taiwan increased in
2007 compared to the rates reported in 20003 and 2005.30
These strains were also resistant to other antimicrobial
agents. This resistance resulted in an increased risk of
administering inappropriate therapy and therefore was
associated with a poor prognosis.31 Colistin and tigecycline
were the main choices for the treatment of infection
caused by these IRAB.9 Although colistin-resistant strains
have been emerging in Korea,32 our survey revealed that
colistin retained its activity against these IRAB.
A baumannii strains carrying blaOxA-23 have been
discovered worldwide8 and are prevalent in Asian-Pacific
regions.13e16 In Taiwan, the epidemiology of acquired
CHDL genes differed among areas11,12 In line with previous
studies performed in a single hospital of central
Taiwan,17,18 blaOxA-23 was the most prevalent CHDL gene in
all 3 teaching hospitals in this area and was rarely found in
other areas. Although naturally occurring and chromosome-
located blaOxA-51 was discovered in all isolates, ISAba1
carrying the promoter was essential for its contribution to
carbapenem resistance.25 Only three isolates in our study
had ISAba1-blaOxA-51. In contrast, most strains (93.3%)
carrying blaOxA-23 had preceding ISAba1, which has been
shown to enhance the expression of blaOxA-23.
33
PFGE studies revealed a minor role of clonal spreading in
the dissemination of isolates with blaOxA-23 in A baumannii
in Taiwan. In agreement with previous studies,19 our study
Dissemination of Acinetobacter baumannii with blaOxA-23 423indicates that the dissemination of blaOxA-23 is attributed to
transposons. Indeed blaOxA-23 can be mobilized by Tn2006,
Tn2007 and Tn2008. Pauline et al reported that Tn2006 was
associated with 20 OXA-23eproducing A baumannii clinical
isolates obtained from 15 countries, including Thailand and
Vietnam.19 Our study also showed that the blaOxA-23 genes
were embedded in Tn2006 in most of our isolates. Although
Tn2008 has been identified only in one isolate from Libya, it
has recently been recognized as the major vehicle carrying
blaOxA-23 in China.
34 However, in our study, isolates with
this genetic structure only accounted for the minority. Two
strains carrying blaOxA-23 had similar structure of Tn2008
but lacked upstream ISAba1. Further studies are warranted
for delineating the sequence of the upstream region.
Four isolates with Tn2008 had identical pulsotype and
were collected from the same hospital (hospital C3), indi-
cating a clonal spreading. Interestingly, all the isolates
bearing Tn2008 had blaOxA-23 detected in plasmids.
However, the localization of blaOxA-23 in a large plasmid of
other isolates cannot be detected using the currently
method. Therefore, the spread of blaOxA-23 via plasmid
dissemination cannot be totally excluded.
In conclusion, in this study, we observed a high preva-
lence of blaOxA-23 in central Taiwan compared with other
areas. The blaOxA-23 is disseminated via complex routes.
The majority of the strains might acquire blaOxA-23 through
the transposition of Tn2006. Clonal spreading played
a minor role in the spread of blaOxA-23. The role of plasmid
dissemination needed to be validated.Acknowledgments
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